Acumen announces pricing of upsized $130 million public offering

Charlottesville, va. and carmel, ind., july 18, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (“acumen”) (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share. all of the shares are being offered by acumen. the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by acumen, are expected to be approximately $130 million. the offering is expected to close on july 21, 2023, subject to the satisfaction of customary closing conditions. in addition, acumen has granted the underwriters a 30-day option to purchase up to an additional 2,516,128 shares of its common stock at the public offering price, less underwriting discounts and commissions.
ABOS Ratings Summary
ABOS Quant Ranking